Published Paper Details:

Abstract: Cancer is characterized by uncontrolled cell growth and acquisition of metastatic properties. Some common forms include breast cancer, lung cancer, prostate cancer, colorectal cancer, and leukemia. Despite significant advances in research and treatment modalities, cancer remains a significant public health challenge, with millions of new cases diagnosed each year. For effective cancer therapy, it is necessary to improve and develop novel strategies for effective delivery of chemotherapeutics to cancer cells. Conventional chemotherapeutic agents accumulate both in normal and tumor cells due to non-specificity. The ultimate goal of cancer therapy is to reduce systemic toxicity and improve the quality of life. The landscape of cancer treatment has improved significantly over the past four decades. Novel treatment with ONCOS-102, developed by Targovax, is a genetically modified adenovirus designed to selectively infect cancer cells in lungs and stimulate anti-tumor immune responses has been developed in recent years. New approaches, such as Photodynamic therapy(PDT) is a minimally invasive treatment that utilizes a photosensitizing agent, light, and oxygen to selectively destroy oral cancer cells. One photosensitizer that has shown promise in oral cancer treatment is 5-aminolevulinic acid of oral cancer. Immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 antibodies, block this interaction, thereby reactivating T cell-mediated anti-tumor immune responses in Breast cancer. With the development of molecular biology and genomics, targeted therapy research has achieved a breakthrough development, including anti-angiogenesis, immune checkpoint inhibitors, and other treatments that are efficient for treatment of cervical cancer. a novel approach to the development of AR antagonists is to target the amino-terminus domain of the AR. The small molecule AR antagonist EPI-001 inhibits protein-protein interactions necessary for AR transcriptional activity. A promising novel approach for treating gastric cancer involves targeting the human epidermal growth factor receptor 2 (HER2), which is overexpressed in approximately 20% of gastric cancers.